
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
CTTI is announcing it has been engaged by the FDA to support its Patient Engagement Collaborative. This collaborative aims at discussing ways in which patients can participate in the FDA's regulatory discussions about medical products. With patient feedback, this collaborative was created and will continue to be used in the future by bringing together representatives to discuss topics on how patients and the FDA can continue working with one another.
Read the full release






